CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
vorinostat +1 moredrug
Likely dose
vorinostat 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00798720
NCT00798720Phase 2Completed
CompareCT.gov

Phase II Study of Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer

University of Wisconsin, Madison·interventional·Posted Nov 26, 2008·Updated Dec 13, 2019

In Brief

A Phase 2 clinical trial evaluating vorinostat and bortezomib for Carcinoma, Non Small Cell Lung. Completed, enrolled 18 participants.

Detailed Summary

The purpose of this study is to evaluate the efficacy of vorinostat and bortezomib in the third line treatment of advanced NSCLC, as well as to assess toxicity (including neuropathy) and tolerability of this regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non Small Cell Lung
Countries--
CollaboratorsMillennium Pharmaceuticals, Inc., Merck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 26, 2008
Enrollment StartDec 1, 2008
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.6 years ago

Interventions

vorinostatdrug

400 mg by mouth once daily for days 1-14 of each 21 day cycle

bortezomibdrug

1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle